

MICHAEL B. ATKINS, MD

DEPUTY CHIEF, DIVISION OF HEMATOLOGY/ONCOLOGY

Beth Israel Deaconess Medical Center

PROFESSOR OF MEDICINE

Harvard Medical School

Boston, Massachusetts

PAST PRESIDENT

SOCIETY FOR IMMUNOTHERAPY OF CANCER

MILWAUKEE, WISCONSIN

Michael B. Atkins, MD, is currently Deputy Chief of the Division of Hematology/Oncology, Director of the Cancer Clinical Trials Office, Director of the Cutaneous Oncology Program, and Director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center's Cancer Center (BIDMC). He is leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and is also a Professor of Medicine at Harvard Medical School.

Dr. Atkins has developed and led several programs at BIDMC and Dana-Farber/Harvard Cancer Center (DF/HCC), most notably in biologic therapy, cutaneous oncology, kidney cancer, and clinical trials. Dr. Atkins' major research interests are immunotherapy of malignancy, with specific emphasis on the use of cytokines such as interleukin 2, treatment of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and antiangiogenic and targeted therapies.

Dr. Atkins is also Director of the DF/HCC Kidney Cancer Specialized Program of Research Excellence (SPORE) grant and co-principal investigator of the DF/HCC Skin Cancer SPORE. He has served on the advisory board of the Melanoma Foundation of New England, the Melanoma Research Foundation and the Kidney Cancer Association, the program committees for the American Society of Clinical Oncology, and American Association for Cancer Research, and he is past president of the Society for Immunotherapy of Cancer.

Dr. Atkins completed his medical education at Tufts University School of Medicine, and post graduate training at the Tufts New England Medical Center Hospital.



Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer
555 E. Wells Street, STE 1100, Milwaukee, WI 53202
Ph: 414-271-2456 ~ info@sitcancer.org
www.sitcancer.org